Free Trial
→ We recommended Palantir in 2021, now we’re recommending this... (From Behind the Markets) (Ad)

Tenaya Therapeutics 11/6/2024 Earnings Report

Tenaya Therapeutics logo
$1.12 -0.02 (-1.33%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Tenaya Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Tenaya Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenaya Therapeutics Announcement Details

Quarter
Date
11/6/2024
Time
After Market Closes

Conference Call Resources

Tenaya Therapeutics Earnings Headlines

H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock
February 4, 2025 | msn.com
Tenaya Therapeutics receives $8M clinical grant from CIRM
February 3, 2025 | markets.businessinsider.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 21, 2025 | WealthPress (Ad)
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
February 3, 2025 | globenewswire.com
Tenaya Therapeutics announces option repricing to retain staff
January 29, 2025 | msn.com
TD Cowen Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)
January 22, 2025 | markets.businessinsider.com
See More Tenaya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email.

About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ:TNYA), a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Tenaya Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles